Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...
All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Arcutis Biotherapeutics has lined up another celeb to tout the benefits of its topical skin medicine Zoryve, adding ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...
A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...
After facing a setback in Germany late last year, Merck & Co.’s European marketing plans for its below-the-skin Keytruda SC are growing more complicated. | After facing a setback in Germany late last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results